**5. Conclusions**

Despite its important advantages, AET is burdened by considerable side effects, which represent a significant problem in BC survivors leading to irregular assumption and discontinuation of therapy, especially in young premenopausal women and during extended therapy. Additionally, women who received adjuvant chemotherapy showed a higher incidence of AET side effects compared to those who did not receive it, but at the same time, they have a lower discontinuation rate, as well as women who received radiotherapy.

Moreover, it is evident from our study that adherence to AET may be improved by trustful physician–patient communication and a good-quality care network, which support women during each step of adjuvant therapy.

The challenge is to be more aware of treatment-related side effects reported by patients, to consider therapies to improve their tolerance and to provide patients with dedicated services, offering them adequate medical and psychological support.

The major strengths of our study are the large sample of patients and the fact that they were all taken in at our Breast Unit, thus limiting the differences in their follow-up and management. On the other hand, the main limitation is that our study is a one-time cross-sectional assessment, and our results came from self-reported information, even though complete anonymity was guaranteed to the patients to avoid untrue answers.

**Author Contributions:** All authors have made substantial contributions to the study conception and design. Material preparation, data collection and analysis were performed by E.S., S.A. and R.R. The first draft of the manuscript was written by R.R., I.C. and M.D., and all authors commented on previous versions of the manuscript. V.E.B. performed the revision of the final manuscript, which has been read and approved by all authors. The entire study was conducted under the supervision of N.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The datasets generated and analyzed during the current study are not publicly available due to privacy reasons but are available from the corresponding author on reasonable request.

**Conflicts of Interest:** The authors declare no conflict of interest.
